MetaCap

Aquestive Therapeutics (AQST) vs Ovid Therapeutics (OVID)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ovid Therapeutics (OVID) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 57.1% versus a loss of 39.5%. Over five years, OVID leads with a -32.5% price change compared with -45.7% for AQST. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $415.2 million), about 1.0 times the size, while Ovid Therapeutics is growing revenue faster (+1181.3% vs -22.6%).

Aquestive Therapeutics converts more of its revenue into profit, with a net margin of -188.1% versus -240.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AQST-39.51%OVID+57.14%
+119%+32%-56%
Nov 21, 20251 yearNov 20, 2026
AQST-42.04%OVID-36.05%
+24%-37%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AQST versus OVID key metrics
MetricAQSTOVID
Share price$3.46$2.20
Market cap$434.88M$415.21M
1-day change-6.61%-5.98%
YTD return-46.44%+34.97%
1-year return-39.51%+57.14%
5-year return-45.68%-32.52%
EPS (TTM)$-0.65$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.55M$7.25M
Revenue growth (YoY)-22.61%+1181.27%
Net income (latest FY)$-83.78M$-17.41M
Gross margin58.35%—
Operating margin-159.50%-585.20%
Net margin-188.09%-240.13%
52-week high$6.74$3.11
52-week low$2.93$1.26
Distance from 52-week high-48.63%-29.15%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+169.65%+179.55%
Average volume2.41M1.98M
Shares outstanding125.69M188.73M
Employees14723
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OVID has outperformed AQST by 96.7 percentage points over the past year.
  • Aquestive Therapeutics is more profitable, keeping -188.1 cents of every revenue dollar as net income versus -240.1 cents for Ovid Therapeutics.
  • Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs -22.61%).

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

About Ovid Therapeutics

OVID stock →

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

AQST vs OVID FAQ

Which is bigger, Aquestive Therapeutics or Ovid Therapeutics?

Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $415.21M for Ovid Therapeutics (OVID).

Which stock has performed better over the past year, AQST or OVID?

OVID returned +57.14% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.

Are Aquestive Therapeutics and Ovid Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons